UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy

British journal of pharmacology, 2006-01, Vol.147 (1), p.1-11

2006

Volltextzugriff (PDF)

Antiviral Agents for Herpes Simplex Virus

Advances in Pharmacology, 2013, Vol.67, p.1-38

2013

Volltextzugriff (PDF)

Recent developments in anti-herpesvirus drugs

British medical bulletin, 2013-06, Vol.106 (1), p.213-249

2013

Volltextzugriff (PDF)

Antiviral drug resistance and helicase–primase inhibitors of herpes simplex virus

Drug resistance updates, 2011-02, Vol.14 (1), p.45-51

2011

Volltextzugriff (PDF)

AVCC 1990–2015 – A journal to combine antiviral biology and antiviral chemistry enters the third era

Antiviral chemistry & chemotherapy, 2015-02, Vol.24 (1), p.1-2

Field, Hugh J

2015

Volltextzugriff (PDF)

A short commentary on the review by Weller and Kuchta: the DNA helicase-primase complex as a target for herpes virus infection

Expert opinion on therapeutic targets, 2013-10, Vol.17 (10), p.1113-1114

Field, Hugh J

2013

Volltextzugriff (PDF)

Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase–primase inhibitor pritelivir

Antiviral research, 2013-11, Vol.100 (2), p.297-299

2013

Volltextzugriff (PDF)

Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections

Future medicinal chemistry, 2014-01, Vol.6 (1), p.45-55

2014

Volltextzugriff (PDF)

Detection of HSV-1 variants highly resistant to the helicase–primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1

Journal of antimicrobial chemotherapy, 2007-08, Vol.60 (2), p.274-279

2007

Volltextzugriff (PDF)

Pharmacokinetics-Pharmacodynamics of the Helicase-Primase Inhibitor Pritelivir following Treatment of Wild-Type or Pritelivir-Resistant Virus Infection in a Murine Herpes Simplex Virus 1 Infection Model

Antimicrobial agents and chemotherapy, 2014-07, Vol.58 (7), p.3843-3852

2014

Volltextzugriff (PDF)

The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1

Antiviral research, 2007-07, Vol.75 (1), p.30-35

2007

Volltextzugriff (PDF)

Mismatch primer-based PCR reveals that helicase–primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor

Journal of antimicrobial chemotherapy, 2010-07, Vol.65 (7), p.1347-1352

2010

Volltextzugriff (PDF)

A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure

Journal of general virology, 2009-08, Vol.90 (8), p.1937-1942

2009

Volltextzugriff (PDF)

Herpes Simplex Virus Helicase—Primase Inhibitors: Recent Findings from the Study of Drug Resistance Mutations

Antiviral chemistry & chemotherapy, 2008-02, Vol.19 (1), p.1-6

2008

Volltextzugriff (PDF)

Effects of therapy using a helicase–primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant

Antiviral research, 2010-07, Vol.87 (1), p.67-73

2010

Volltextzugriff (PDF)

The helicase-primase complex as a target for effective herpesvirus antivirals

Advances in experimental medicine and biology, 2013, Vol.767, p.145

2013

Volltextzugriff (PDF)

The effect of passive immunization on the acute phase of infection in a murine model of EHV‐1

The FASEB journal, 2021-05, Vol.35 (S1), p.n/a, Article fasebj.2021.35.S1.00187

2021

Volltextzugriff (PDF)

Antiviral Chemistry & Chemotherapy's Current Antiviral Agents FactFile (2nd Edition)

Antiviral chemistry & chemotherapy, 2008, Vol.19 (2), p.49-50

Field, Hugh J

2008

Volltextzugriff (PDF)

A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase–primase inhibitors in their mode of interaction with the antiviral target

Journal of antimicrobial chemotherapy, 2008-05, Vol.61 (5), p.1044-1047

2008

Volltextzugriff (PDF)

High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1

Antiviral chemistry & chemotherapy, 2007, Vol.18 (1), p.13-23

2007

Volltextzugriff (PDF)

Development of a quantitative real-time TaqMan PCR assay for testing the susceptibility of feline herpesvirus-1 to antiviral compounds

Journal of virological methods, 2008-09, Vol.152 (1), p.85-90

2008

Volltextzugriff (PDF)

Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase–primase inhibitors, variously affect virus growth rate and pathogenicity

Antiviral research, 2008-10, Vol.80 (1), p.81-85

2008

Volltextzugriff (PDF)

Penciclovir is a potent inhibitor of feline herpesvirus-1 with susceptibility determined at the level of virus-encoded thymidine kinase

Antiviral research, 2008-06, Vol.78 (3), p.268-274

2008

Volltextzugriff (PDF)

Characterization of Viraemic Cells in a Murine Model of EHV‐1 Infection

The FASEB journal, 2020-04, Vol.34 (S1), p.1-1

2020

Volltextzugriff (PDF)

Immunopathology in Lungs after Intranasal Challenge with Live Virus in an EHV‐1 Murine Model: Lessons Learned from Unexpected Findings

The FASEB journal, 2020-04, Vol.34 (S1), p.1-1

2020

Volltextzugriff (PDF)

1 – 25 von 260

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(226)
Mit Volltextzugriff
(224)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(259)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(137)
Life Sciences & Biomedicine
(112)
Humans
(58)
Biological And Medical Sciences
(55)
Animals
(53)
Medical Sciences
(39)
Antiviral Agents - Pharmacology
(38)
Antiviral Agents
(37)
Female
(33)
Mice
(33)
Pharmacology. Drug Treatments
(32)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(31)
Virology
(31)
Pharmacology & Pharmacy
(30)
Antiviral Agents - Therapeutic Use
(25)
Mice, Inbred Balb C
(22)
Physical Sciences
(22)
Microbiology
(20)
Geography, Physical
(18)
Geology
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy

Antiviral Agents for Herpes Simplex Virus

Recent developments in anti-herpesvirus drugs

Antiviral drug resistance and helicase–primase inhibitors of herpes simplex virus

AVCC 1990–2015 – A journal to combine antiviral biology and antiviral chemistry enters the third era

A short commentary on the review by Weller and Kuchta: the DNA helicase-primase complex as a target for herpes virus infection

Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase–primase inhibitor pritelivir

Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections

Detection of HSV-1 variants highly resistant to the helicase–primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1

Pharmacokinetics-Pharmacodynamics of the Helicase-Primase Inhibitor Pritelivir following Treatment of Wild-Type or Pritelivir-Resistant Virus Infection in a Murine Herpes Simplex Virus 1 Infection Model

The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1

Mismatch primer-based PCR reveals that helicase–primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor

A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure

Herpes Simplex Virus Helicase—Primase Inhibitors: Recent Findings from the Study of Drug Resistance Mutations

Effects of therapy using a helicase–primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant

The helicase-primase complex as a target for effective herpesvirus antivirals

The effect of passive immunization on the acute phase of infection in a murine model of EHV‐1

Antiviral Chemistry & Chemotherapy's Current Antiviral Agents FactFile (2nd Edition)

A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase–primase inhibitors in their mode of interaction with the antiviral target

High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1

Development of a quantitative real-time TaqMan PCR assay for testing the susceptibility of feline herpesvirus-1 to antiviral compounds

Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase–primase inhibitors, variously affect virus growth rate and pathogenicity

Penciclovir is a potent inhibitor of feline herpesvirus-1 with susceptibility determined at the level of virus-encoded thymidine kinase

Characterization of Viraemic Cells in a Murine Model of EHV‐1 Infection

Immunopathology in Lungs after Intranasal Challenge with Live Virus in an EHV‐1 Murine Model: Lessons Learned from Unexpected Findings

Suchergebnisse filtern